Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Luderman KD, Conroy JL, Free RB, Southall N, Ferrer M, Sanchez-Soto M, Moritz AE, Willette BKA, Fyfe TJ, Jain P, Titus S, Hazelwood LA, Aubé J, Lane JR, Frankowski KJ, Sibley DR.

Mol Pharmacol. 2018 Oct;94(4):1197-1209. doi: 10.1124/mol.118.113175. Epub 2018 Aug 1.

2.

A new era of rationally designed antipsychotics.

Sibley DR, Shi L.

Nature. 2018 Mar 8;555(7695):170-172. doi: 10.1038/d41586-018-02328-z. No abstract available.

PMID:
29517027
3.

Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor.

Chun LS, Vekariya RH, Free RB, Li Y, Lin DT, Su P, Liu F, Namkung Y, Laporte SA, Moritz AE, Aubé J, Frankowski KJ, Sibley DR.

Front Synaptic Neurosci. 2018 Feb 21;10:2. doi: 10.3389/fnsyn.2018.00002. eCollection 2018.

4.

The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.

Verma RK, Abramyan AM, Michino M, Free RB, Sibley DR, Javitch JA, Lane JR, Shi L.

PLoS Comput Biol. 2018 Jan 16;14(1):e1005948. doi: 10.1371/journal.pcbi.1005948. eCollection 2018 Jan.

5.

Irwin J Kopin.

Goldstein DS, Sibley DR.

Neuropsychopharmacology. 2017 Dec;42(13):2656. doi: 10.1038/npp.2017.208. No abstract available.

PMID:
29123235
6.

The Dopamine D5 Receptor Is Involved in Working Memory.

Carr GV, Maltese F, Sibley DR, Weinberger DR, Papaleo F.

Front Pharmacol. 2017 Oct 6;8:666. doi: 10.3389/fphar.2017.00666. eCollection 2017.

7.

Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Moritz AE, Free RB, Sibley DR.

Cell Signal. 2018 Jan;41:75-81. doi: 10.1016/j.cellsig.2017.07.003. Epub 2017 Jul 14. Review.

PMID:
28716664
8.

Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Kumar V, Moritz AE, Keck TM, Bonifazi A, Ellenberger MP, Sibley CD, Free RB, Shi L, Lane JR, Sibley DR, Newman AH.

J Med Chem. 2017 Feb 23;60(4):1478-1494. doi: 10.1021/acs.jmedchem.6b01688. Epub 2017 Feb 10.

9.

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Zou MF, Keck TM, Kumar V, Donthamsetti P, Michino M, Burzynski C, Schweppe C, Bonifazi A, Free RB, Sibley DR, Janowsky A, Shi L, Javitch JA, Newman AH.

J Med Chem. 2016 Apr 14;59(7):2973-88. doi: 10.1021/acs.jmedchem.5b01612. Epub 2016 Apr 1.

10.

Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors.

Michino M, Free RB, Doyle TB, Sibley DR, Shi L.

Chem Commun (Camb). 2015 May 21;51(41):8618-21. doi: 10.1039/c5cc02204e.

11.

PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.

Dix AV, Conroy JL, George Rosenker KM, Sibley DR, Appella DH.

ACS Med Chem Lett. 2015 Mar 13;6(4):425-9. doi: 10.1021/ml500478m. eCollection 2015 Apr 9.

12.

Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells.

Yang S, Yang Y, Yu P, Yang J, Jiang X, Villar VA, Sibley DR, Jose PA, Zeng C.

Free Radic Res. 2015 Apr;49(4):397-410. doi: 10.3109/10715762.2015.1006215. Epub 2015 Mar 5.

13.

Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Conroy JL, Free RB, Sibley DR.

ACS Chem Neurosci. 2015 Apr 15;6(4):681-92. doi: 10.1021/acschemneuro.5b00020. Epub 2015 Feb 20.

14.

Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.

Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR.

Eur Neuropsychopharmacol. 2015 Sep;25(9):1448-61. doi: 10.1016/j.euroneuro.2014.11.013. Epub 2014 Nov 29.

15.

Evidence against dopamine D1/D2 receptor heteromers.

Frederick AL, Yano H, Trifilieff P, Vishwasrao HD, Biezonski D, Mészáros J, Urizar E, Sibley DR, Kellendonk C, Sonntag KC, Graham DL, Colbran RJ, Stanwood GD, Javitch JA.

Mol Psychiatry. 2015 Nov;20(11):1373-85. doi: 10.1038/mp.2014.166. Epub 2015 Jan 6.

16.

Dopamine D₁-like receptors regulate the α₁A-adrenergic receptor in human renal proximal tubule cells and D₁-like dopamine receptor knockout mice.

Ennis RC, Asico LD, Armando I, Yang J, Feranil JB, Jurgens JA, Escano CS Jr, Yu P, Wang X, Sibley DR, Jose PA, Villar VA.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1238-48. doi: 10.1152/ajprenal.00119.2014. Epub 2014 Oct 22.

17.

(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR.

Psychopharmacology (Berl). 2015 Mar;232(5):917-30. doi: 10.1007/s00213-014-3726-8. Epub 2014 Sep 18.

18.

Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, Barnaeva E, Ferrer M, Javitch JA, Beuming T, Shi L, Southall NT, Marugan JJ, Sibley DR.

Mol Pharmacol. 2014 Jul;86(1):96-105. doi: 10.1124/mol.113.090563. Epub 2014 Apr 22.

19.

Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.

Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE, Southall N, Ferrer M, Titus S, Zheng W, Sibley DR, Marugan JJ.

J Med Chem. 2014 Apr 24;57(8):3450-63. doi: 10.1021/jm500126s. Epub 2014 Apr 10.

20.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

21.

Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists.

Xiao J, Free RB, Barnaeva E, Conroy J, Doyle T, Bryant-Genevier M, Taylor MK, Southall N, Hu X, Ferrer M, Titus S, Zheng W, Sibley DR, Marugan JJ.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 25 [updated 2013 Sep 3].

22.

D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, Sibley DR.

Mol Pharmacol. 2013 Aug;84(2):190-200. doi: 10.1124/mol.113.085175. Epub 2013 May 16.

23.

Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P.

Int J Neuropsychopharmacol. 2013 Mar;16(2):445-58. doi: 10.1017/S1461145712000661. Epub 2012 Jul 25.

24.

Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P.

Biochem Pharmacol. 2012 Oct 1;84(7):882-90. doi: 10.1016/j.bcp.2012.06.023. Epub 2012 Jul 3. Review.

25.

Dopaminergic signaling in the cochlea: receptor expression patterns and deletion phenotypes.

Maison SF, Liu XP, Eatock RA, Sibley DR, Grandy DK, Liberman MC.

J Neurosci. 2012 Jan 4;32(1):344-55. doi: 10.1523/JNEUROSCI.4720-11.2012.

26.

Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Skinbjerg M, Sibley DR, Javitch JA, Abi-Dargham A.

Biochem Pharmacol. 2012 Jan 15;83(2):193-8. doi: 10.1016/j.bcp.2011.09.008. Epub 2011 Sep 16. Review.

27.

N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH.

J Med Chem. 2011 May 26;54(10):3581-94. doi: 10.1021/jm200288r. Epub 2011 May 2.

28.

Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions.

Reichart DL, Hinkle RT, Lefever FR, Dolan ET, Dietrich JA, Sibley DR, Isfort RJ.

BMC Musculoskelet Disord. 2011 Jan 26;12:27. doi: 10.1186/1471-2474-12-27.

29.

Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice.

Kramer PF, Christensen CH, Hazelwood LA, Dobi A, Bock R, Sibley DR, Mateo Y, Alvarez VA.

J Neurosci. 2011 Jan 5;31(1):126-32. doi: 10.1523/JNEUROSCI.4287-10.2011.

30.

Lack of renal dopamine D5 receptors promotes hypertension.

Asico L, Zhang X, Jiang J, Cabrera D, Escano CS, Sibley DR, Wang X, Yang Y, Mannon R, Jones JE, Armando I, Jose PA.

J Am Soc Nephrol. 2011 Jan;22(1):82-9. doi: 10.1681/ASN.2010050533. Epub 2010 Nov 4.

31.

Constitutive phosphorylation by protein kinase C regulates D1 dopamine receptor signaling.

Rankin ML, Sibley DR.

J Neurochem. 2010 Dec;115(6):1655-67. doi: 10.1111/j.1471-4159.2010.07074.x. Epub 2010 Nov 19.

32.

Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice.

Wang X, Luo Y, Escano CS, Yang Z, Asico L, Li H, Jones JE, Armando I, Lu Q, Sibley DR, Eisner GM, Jose PA.

Hypertension. 2010 Jun;55(6):1431-7. doi: 10.1161/HYPERTENSIONAHA.109.148643. Epub 2010 Apr 19.

33.

Identification of RanBP 9/10 as interacting partners for protein kinase C (PKC) gamma/delta and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation.

Rex EB, Rankin ML, Yang Y, Lu Q, Gerfen CR, Jose PA, Sibley DR.

Mol Pharmacol. 2010 Jul;78(1):69-80. doi: 10.1124/mol.110.063727. Epub 2010 Apr 15.

34.

Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.

Skinbjerg M, Seneca N, Liow JS, Hong J, Weinshenker D, Pike VW, Halldin C, Sibley DR, Innis RB.

Synapse. 2010 Sep;64(9):699-703. doi: 10.1002/syn.20781.

35.

D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.

Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB.

Neuroimage. 2010 May 1;50(4):1402-7. doi: 10.1016/j.neuroimage.2010.01.055. Epub 2010 Jan 22.

36.

G protein-coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and signaling independently of receptor phosphorylation.

Namkung Y, Dipace C, Urizar E, Javitch JA, Sibley DR.

J Biol Chem. 2009 Dec 4;284(49):34103-15. doi: 10.1074/jbc.M109.055707. Epub 2009 Oct 8.

37.

G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor.

Namkung Y, Dipace C, Javitch JA, Sibley DR.

J Biol Chem. 2009 May 29;284(22):15038-51. doi: 10.1074/jbc.M900388200. Epub 2009 Mar 30.

38.

Arrestin3 mediates D(2) dopamine receptor internalization.

Skinbjerg M, Ariano MA, Thorsell A, Heilig M, Halldin C, Innis RB, Sibley DR.

Synapse. 2009 Jul;63(7):621-4. doi: 10.1002/syn.20636. No abstract available.

39.

Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.

Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR.

Synapse. 2009 Jun;63(6):462-75. doi: 10.1002/syn.20626.

40.

Identifying novel protein-protein interactions using co-immunoprecipitation and mass spectroscopy.

Free RB, Hazelwood LA, Sibley DR.

Curr Protoc Neurosci. 2009 Jan;Chapter 5:Unit 5.28. doi: 10.1002/0471142301.ns0528s46.

41.

D5 dopamine receptors are required for dopaminergic activation of phospholipase C.

Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, Undieh AS.

Mol Pharmacol. 2009 Mar;75(3):447-53. doi: 10.1124/mol.108.053017. Epub 2008 Dec 1.

42.

Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+,K+-ATPase.

Hazelwood LA, Free RB, Cabrera DM, Skinbjerg M, Sibley DR.

J Biol Chem. 2008 Dec 26;283(52):36441-53. doi: 10.1074/jbc.M805520200. Epub 2008 Nov 4.

43.

Mechanism and time course of cocaine-induced long-term potentiation in the ventral tegmental area.

Argilli E, Sibley DR, Malenka RC, England PM, Bonci A.

J Neurosci. 2008 Sep 10;28(37):9092-100. doi: 10.1523/JNEUROSCI.1001-08.2008.

44.

Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.

Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, Pike VW, Halldin C, Innis RB.

Synapse. 2008 Oct;62(10):756-63. doi: 10.1002/syn.20549.

45.

Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization.

Karlsson RM, Hefner KR, Sibley DR, Holmes A.

Psychopharmacology (Berl). 2008 Sep;200(1):117-27. doi: 10.1007/s00213-008-1165-0. Epub 2008 Jul 4.

46.

Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Seneca N, Skinbjerg M, Zoghbi SS, Liow JS, Gladding RL, Hong J, Kannan P, Tuan E, Sibley DR, Halldin C, Pike VW, Innis RB.

Synapse. 2008 Sep;62(9):700-9. doi: 10.1002/syn.20544.

47.

Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells.

Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA.

J Clin Invest. 2008 Jun;118(6):2180-9. doi: 10.1172/JCI33637. Erratum in: J Clin Invest. 2008 Aug;118(8):2986. Gildea, John J [added].

48.

Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.

O'Sullivan GJ, Dunleavy M, Hakansson K, Clementi M, Kinsella A, Croke DT, Drago J, Fienberg AA, Greengard P, Sibley DR, Fisone G, Henshall DC, Waddington JL.

Neuropharmacology. 2008 Jun;54(7):1051-61. doi: 10.1016/j.neuropharm.2008.02.011. Epub 2008 Feb 21.

49.

D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP.

Kim OJ, Ariano MA, Namkung Y, Marinec P, Kim E, Han J, Sibley DR.

J Neurochem. 2008 Jul;106(1):83-95. doi: 10.1111/j.1471-4159.2008.05348.x. Epub 2008 Jul 1.

50.

Ethanol regulation of D(1) dopamine receptor signaling is mediated by protein kinase C in an isozyme-specific manner.

Rex EB, Rankin ML, Ariano MA, Sibley DR.

Neuropsychopharmacology. 2008 Nov;33(12):2900-11. doi: 10.1038/npp.2008.16. Epub 2008 Feb 20.

Supplemental Content

Loading ...
Support Center